Navigation Links
Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Date:7/29/2008

and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-KSB for the year ended December 31, 2007, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. The foregoing list of factors is not exhaustive. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations Contacts:

Patrick T. Mooney, M.D.

Chairman & CEO

Echo Therapeutics

508-530-0329

Melanie Friedman

Stern Investor Relations

212-362-1200


'/>"/>
SOURCE Echo Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
(Date:2/27/2015)... 2015 Those who self-injure, ... misunderstood, misdiagnosed and therefore aren’t receiving effective ... Jacksonville-based addiction treatment center Lakeview Health ... acclaimed Lakeview Professional Lecture Series to counselors, ... this complicated condition. , “Self-injurious ...
(Date:2/27/2015)... 2015 Clinovo, a leading provider of ... Data Capture (EDC) at the CALBIO2015 conference ... and March 3rd at Booth # 141. , ... CRF and edit-check builder allowing Clinical Trials Managers to ... days, without any programming experience. Clinovo’s new pricing model ...
(Date:2/27/2015)... February 27, 2015 Pipette.com announces their ... , price is only valid until the end of ... looking for a vortex mixer that allows for absolute ... founded in 1954 and is headquartered in Bohemia, New ... shakers, as well as other rockers, incubators, and hybridization ...
(Date:2/27/2015)... 27, 2015 Undocumented farmworkers are ... to use Medicaid, the federal health insurance program ... a new study from UC Davis Health System. ... of farmworker use of Medicaid, which provides coverage ... documentation status, was having children. , “Undocumented ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3
... HOUSTON, May 15 The American Association ... of Endocrinology (AACE and ACE) today released ... The position is a strong statement in ... collaboration between physicians and industry.(Logo: ...
... Bertalan Mesko, medical blogger and health 2.0 consultant, ... Diabetes 2.0 , that aims to provide diabetes ... package containing quality and selected diabetes information. It lists ... sites, among others, from the best quality. All the ...
... announcement that President Obama nominated Dr. Thomas Frieden ... Prevention, the Center for Consumer Freedom,s Senior Research ... is unfortunate that President Obama choose to put ... overzealous activist who doesn,t give any consideration to ...
... The best traders understand their psychology and how ... coach Ari Kiev, M.D. said in his remarks ... leading provider of global agency brokerage and investment ... Kiev Consulting, coaches institutional traders and portfolio managers ...
... young children, before five years of age, could save ... costs, according to an examination of childhood health conducted ... Public Health. The results are published in the May ... "Our review found convincing evidence that the four ...
... Leader Provides Major Boost to Organization that Helps Wounded ... Boston announced today that technology and innovation leader Raytheon ... to the organization. The gift will go directly towards ... ground last October on the grounds of the Veterans ...
Cached Medicine News:Health News:Major Physician Group Issues Statement in Support of Physician/Industry Relationships 2Health News:Major Physician Group Issues Statement in Support of Physician/Industry Relationships 3Health News:Psychiatrist and Trading Coach Dr. Ari Kiev Discusses Psychology of Peak Performance, Risk Management at ConvergEx Forum 2Health News:Early childhood health interventions could save billions in health costs later in life 2Health News:Early childhood health interventions could save billions in health costs later in life 3Health News:Raytheon Donates $100,000 to Fisher House Boston 2
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
Gold radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... Combined Advanced Technologies, The UroMax Ultra ... combination of high pressure and low ... process yields a remarkably strong material ... pressure balloon materials., Non-Compliant Balloons, A ...
Medicine Products: